Qu Yixian, a reporter from the Economic observation Network.On December 27, Fosun Health announced the opening of its online platform to register the vaccination intention of Fubitai bivalent vaccine in Hong Kong. From now on, users can log on to Fosun Health platform or WeChat Mini Programs and find the entrance of "COVID-19 Vaccine" on the home page to register the vaccination intention of Fubitai bivalent vaccine in Hong Kong. after a successful appointment, you can go to Hong Kong to receive Fubitai bivalent vaccine at your own expense after the formal resumption of customs clearance between the two places.
On March 16, 2020, Shanghai Fosun Pharmaceutical and Germany's BioNTech announced that they had reached a strategic cooperation in mRNA vaccine development. Shanghai Fosun Pharmaceutical was authorized by BioNTech to exclusively develop and commercialize COVID-19 vaccine based on its proprietary mRNA technology platform in China, Hong Kong, Macao and Taiwan.
In December 2022, mRNA COVID-19 vaccine BNT162b2 and Fupitai bivalent vaccine were officially registered as drugs / products (biological products) in Hong Kong, China.
Fubitai bivalent vaccine is an iteration and supplement of Fubitai BNT162b2, which can effectively deal with Omicron mutant. Each dose of Fubitai bivalent vaccine contains 15 micrograms of mRNA encoding the spike protein of the original strain and 15 micrograms of mRNA encoding the spike protein of the Omicron BA.4/BA.5 mutant strain.
Clinical studies and real-world data show that Fubitai bivalent vaccine as an enhancer can produce a strong neutralizing antibody response against Omicron BA.1, BA.2 and BA.4/BA.5 variants as well as the original strain. Compared with the original strain, the vaccine has better immunogenicity and broad spectrum, and can fully cover the Omicron mutant.
According to the phase 3 clinical trial of Fubitai bivalent vaccine announced earlier by BioNTech, Fubitai bivalent vaccine as an enhancer is beneficial to strengthen the protection of the elderly population. One month after vaccination, the clinical trial data of Fubitai bivalent vaccine showed that the clinical trial data of Fubitai bivalent vaccine were good, the neutralizing antibody of adults aged 18-55 increased 9.5 times, and the neutralizing antibody of people over 55 increased by 13.2 times. It can provide better protection effect.